Supporting health plan clinical preparation and financial modeling.
Different paths to formulary decision-making.
Reversing non-formulary status will usually require new data.
Tackling the subjective limits of value proposition.
Payers not looking to favor one product.
Potential for quality equivalent to economies of scale.